BBIO Stock Recent News

We put BridgeBio Pharma, Inc. in the spotlight for the first time since last summer as the company continues to have buyout speculation around it. BridgeBio also has had some positive recent trial developments and executed a needed capital raise in March.

PALO ALTO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas, NV on Wednesday, May 10 at 10:00 am PT.

Growth stocks have been under heavy pressure over the past year. A handful of biotech companies have defied this broader downturn, however.

CNBC's Meg Tirrell joins 'Power Lunch' to report on Bridgebio's stock surge and pharma returns.

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.

- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023

Markets were mixed, with large caps rising as small caps gave up ground. BridgeBio Pharma showed positive trial results for a treatment for a disease that limits growth.

At least two biotech stocks are seeing increased scrutiny in the options pits, with BridgeBio Pharma  Inc (NASDAQ:BBIO) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions following their respective drug updates.

BridgeBio Pharma Inc shares have soared more than 55% after the company announced positive data from a Phase 2 clinical trial for its investigational therapy infigratinib in children with achondroplasia, a form of short-limbed dwarfism. Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source, BridgeBio noted in a statement.